Find an Article

Filter articles

Applied Filters

Showing 751 to 760 of 985 results

A brave new world for supplementary protection certificates

01-01-2012Mike Snodin and Michael Pears

Advocate-General Verica Trstenjak has delivered an opinion in the case of Neurim Pharmaceuticals that, if followed by the Court of Justice of the EU, will profoundly liberalise the law governing SPCs in Europe.

The right foundations: the importance of prior art searches

01-01-2012Matt McBride

LSIPR talks to Matt McBride about how Science IP can help businesses ensure their patent plans get off to the best possible start.

A step into the unknown: India's first compulsory license

India01-01-2012Archana Shanker

For the first time in the history of the Indian patent system, a compulsory licence has been granted. Archana Shanker considers the implications.

Licensors: facing unexpected bumps in the road

China, Japan, Taiwan, US01-01-2012Daniel Papst

The licensing of patents across the world requires dealing with various different licensors from diverse cultural backgrounds. But that’s not always easy, says Daniel Papst.

Surprise patent setback stuns biotech

US01-01-2012BiotechnologyPaul Sutton

Two recent US court decisions have important implications for patent attorney practice as well as for the biotech sector, as Paul Sutton reports.

Shock to the system: a compulsory licence for Nexavar

India01-01-2012Mita Sheikh

The Nexavar decision will be welcomed by patients in terms of affordability, but is a compulsory licence the best way to address the issue? Nita Sheikh asks the question.

New course for punitive damages in Canada

Canada01-01-2012Marek Nitoslawski and David Turgeon

Canadian courts have, traditionally, not been inclined to award punitive damages in IP cases but this may be about to change. Marek Nitoslawski and David Turgeon investigate.

Compulsory licensing: the prologue

India01-01-2012Ranjna Mehta-Dutt and Shukadev Khuraijam

Generic pharmaceutical manufacturer Natco has secured a compulsory licence to produce cancer drug Nexavar for the Indian market. Ranjna Mehta-Dutt and Shukadev Khuraijam report.

CIPA Congress, Lancaster London Hotel, London


The 16th Annual CIPA Congress boasted an impressive programme of important speakers, and witnessed lively debate on patent developments in the UK and further afield.

NPEs: malevolent or misunderstood?


Patents not only protect valuable technology, they are increasingly becoming assets in their own right, traded and licensed in a standalone market. WIPR looks at Intellectual Ventures and RPX Corporation to find out more about NPEs.

Showing 751 to 760 of 985 results